Skip to main navigation Skip to search Skip to main content

Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: A cross-sectional study

  • Rajendra Prasad Janapatla
  • , Mei Hua Hsu
  • , Chyi Liang Chen
  • , Sung Hsi Wei
  • , Ming Jia Yu
  • , Lin Hui Su
  • , Tzou Yien Lin
  • , Cheng Hsun Chiu

Research output: Contribution to journalArticlepeer-review

Abstract

In 500 children aged ≤10 years after 13-valent pneumococcal conjugate vaccine (PCV)13 immunisation in different schedules, serotypes 19A-specific and 19F-specific immunoglobulin G (IgG) were predicted to persist above 0.35 μg/mL for ≥10 years in all groups, likely due to PCV13-induced memory with natural boosting from residual diseases and colonisation. Generally, serotype-specific IgG could persist above 0.35 μg/mL longer (≥5 years) in the catch-up group than in the 2+1 and 3+1 immunisation groups. 14.5% of the carriage isolates belonged to PCV13 serotypes; statistical analysis revealed that a high serum IgG level (>10.96 μg/mL) will be required to eliminate the point-prevalence nasopharyngeal carriage of serotype 19A.

Original languageEnglish
Pages (from-to)689-692
Number of pages4
JournalThorax
Volume75
Issue number8
DOIs
Publication statusPublished - Aug 1 2020
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • bacterial infection
  • clinical epidemiology
  • infection control
  • paediatric lung disaese
  • pneumonia
  • respiratory infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: A cross-sectional study'. Together they form a unique fingerprint.

Cite this